Collection: GLUCOSE REGULATION THERAPY

Tirzepatide is a novel dual agonist peptide that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It works by increasing insulin available and decreasing glucagon (a hormone that controls the amount of glucose made by the liver) available in the body. 

Weight Loss Benefits:

Appetite Suppression: Tirzepatide's activation of GLP-1 receptors in the hypothalamus, a region of the brain responsible for regulating appetite, results in increased satiety and decreased hunger. This suppression of appetite is one of the primary mechanisms by which tirzepatide contributes to weight loss.

Delayed Gastric Emptying: GLP-1 receptor activation by tirzepatide also slows down gastric emptying, which in turn reduces the rate at which nutrients are absorbed. This effect can help individuals feel fuller for longer periods, leading to a reduced caloric intake and subsequent weight loss.

Improved Lipid Metabolism: Tirzepatide's action on GIP receptors found in adipose tissue, liver, and other peripheral tissues helps enhance lipid metabolism. This leads to a decrease in fat storage and an increase in the utilization of stored fat for energy, contributing to weight loss.

Enhanced Glucose Homeostasis: As a dual GIP and GLP-1 receptor agonist, tirzepatide improves glucose homeostasis by stimulating insulin secretion in response to food intake and suppressing glucagon secretion. This improved glucose regulation can contribute to weight loss by promoting a more efficient use of energy sources and reducing the risk of insulin resistance and weight gain.

Reduced Inflammation: Studies have suggested that tirzepatide may reduce inflammation, which is often associated with obesity and metabolic dysfunction. By lowering inflammation, tirzepatide may help create a more favorable metabolic environment for weight loss.

The weight loss effects of tirzepatide have been demonstrated in clinical trials involving patients with type 2 diabetes. In these trials, patients experienced significant reductions in body weight compared to those receiving other antidiabetic medications or placebo. The dual agonist mechanism of tirzepatide, targeting both GLP-1 and GIP receptors, appears to be a key factor in its potent weight loss effects.

CONTENT & POTENCY

Injectable
10mg lyophilized peptide provided in a vial 

20mg lyophilized peptide provided in a vial 

40mg lyophilized peptide provided in a vial 

Reconstitute each vial with 1ml Bacteriostatic Water*

*Bacteriostatic water purchased separately